China, Hong Kong stocks rise on healthcare, tech advance
China, Hong Kong stocks rise on healthcare, tech advance Update closing prices
SHANGHAI, Aug 20 (Reuters) - China and Hong Kong stocks rose on Thursday, as healthcare stocks surged and tech shares rebounded from a selloff, amid a broader recovery across Asia.
** China's large-cap CSI300 Index .CSI300 finished the session up 0.1%, after tumbling 3% on Wednesday. The Shanghai Composite Index .SSEC rose 0.2%.
** In Hong Kong, Hang Seng .HSI climbed 0.8% after a nearly flat session on Wednesday.
** Investors drew solace from strength in neighbouring markets following the global tech selloff in the previous session. South Korea's Kospi Index .KS11 jumped 6% while Japan's stock market gained 1.4%.
** Sentiment was also aided by a fresh batch of Chinese companies - including Foxconn Industrial Internet Co 601138.SS and CCCC Design & Consulting 600720.SS - announcing share buybacks or purchases.
** Healthcare stocks surged in both China and Hong Kong after Moderna MRNA.O and Merck MRK.N on Wednesday announced a major success in a new field of cancer treatment that sent Moderna's shares surging as much as 160%, while Merck jumped 12%.
** China's CSI Vaccine and Biotech Index .CSI931992 shot up 9%, while Hong Kong's Hang Seng Innovative Drug Index .HSIDI advanced more than 4%.
** Meanwhile, tech shares clawed back some of Wednesday's losses.
** The STAR100 Index .STAR100 gained 2% after a 7% loss, while Hong Kong's AI Index .HSAIT firmed 2.3%.
** But shares of Chinese humanoid robot maker Unitree 688836.SS tumbled 19% after soaring more than fivefold in a blockbuster trading debut in Shanghai on Wednesday.
(By Shanghai Newsroom; Edited by Harikrishnan Nair)
Recent news on Moderna
See all newsTrading Day: Maximum pAIn
Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall (updated)
Brief: Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42%
Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%